Post-earnings recap
Reported
Thu, Jul 27, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Bristol Myers Squibb's earnings report showed a slight miss on EPS, which contributed to a 3.11% decline in stock price. Investors may be reacting to management's cautious tone regarding market challenges and the lack of updated guidance. The focus will likely shift to the company's pipeline and future product launches as key factors for recovery.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.74 | N/A | -1.36% |
Management expressed concerns about market conditions affecting performance. They reiterated their focus on future product launches and pipeline strength.
Management highlighted ongoing challenges in the market.
They emphasized the importance of pipeline developments moving forward.